Exchange: NASDAQ·Updated 06:28 PM EDT
News
all
press releases
Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers
Trump's MFN push expands to nine mid-sized drugmakers, bringing 26 companies under agreements covering 89% of the branded drug market.
Zacks
More News
$19.6B Infusion In US Plants With Lower Drug Prices: White House’s Deal With Mid-size Drugmakers
Under the deals, the drug makers would charge Americans no more than the lowest price paid in other rich countries.
Stocktwits
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines
BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding...
Business Wire
BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA (zanidatamab), in combination with chemotherapy, with and without TEVIMBRA...
Business Wire
Generative "AI" Macro Data Shows U.S. Impacts
There are solid gains to knowledge workers. But smaller ones outside it.
Zacks
BeOne Medicines Ltd. - Sponsored ADR (ONC) is a Great Momentum Stock: Should You Buy?
Does BeOne Medicines Ltd. - Sponsored ADR (ONC) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks
JAZZ, ONC, ZYME Stocks In Focus After FDA Approves Gastroesophageal Cancer Therapy
The FDA approved Jazz Pharma’s Ziihera with chemotherapy, with or without BeOne’s Tevimbra, as an initial treatment for advanced HER2-positive gastroesophageal cancer.
Stocktwits
BeOne Medicines Announces U.S. FDA Approval for TEVIMBRA-Based Regimen for First-Line HER2+ GEA
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for TEVIMBRA (tislelizumab) in combination with ZIIHERA (zanidatamab) and...
Business Wire
BeOne Medicines Ltd. - Sponsored ADR (ONC) Now Trades Above Golden Cross: Time to Buy?
Is it a good or bad thing when a stock experiences a golden cross technical event?
Zacks
BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries
BeOne Medicines Ltd. (BeOne) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, together with the BeOne Care Foundation, a nonprofit charitable foundation, and The Max Foundation, a leading global health nonprofit organization, today announced the renewal of their partnership...
Business Wire

Advertisement|Remove ads.